Traws Pharma (NASDAQ:TRAW) Announces Earnings Results

Traws Pharma (NASDAQ:TRAW) announced its quarterly earnings data on Friday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.18, FiscalAI reports.

Traws Pharma Price Performance

Traws Pharma stock traded down $0.03 during mid-day trading on Friday, reaching $0.57. 76,075 shares of the company traded hands, compared to its average volume of 110,422. The firm’s 50 day moving average price is $0.73 and its 200 day moving average price is $1.37. The firm has a market capitalization of $8.65 million, a price-to-earnings ratio of -0.34 and a beta of 1.57. Traws Pharma has a 52-week low of $0.43 and a 52-week high of $3.27.

Institutional Investors Weigh In On Traws Pharma

Large investors have recently modified their holdings of the stock. Squadron Capital Management LLC purchased a new position in shares of Traws Pharma during the fourth quarter valued at about $806,000. Ikarian Capital LLC raised its stake in Traws Pharma by 2,280.0% in the fourth quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after buying an additional 649,649 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Traws Pharma by 121.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after buying an additional 400,000 shares during the period. Boothbay Fund Management LLC purchased a new stake in Traws Pharma in the fourth quarter worth about $220,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Traws Pharma in the fourth quarter worth about $175,000. Institutional investors own 7.95% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on TRAW shares. HC Wainwright restated a “negative” rating and issued a $1.00 target price on shares of Traws Pharma in a report on Thursday, June 18th. LADENBURG THALM/SH SH lowered shares of Traws Pharma from a “buy” rating to a “neutral” rating in a report on Monday, June 15th. Citigroup lowered shares of Traws Pharma to a “neutral” rating in a report on Monday, June 15th. Weiss Ratings cut Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Finally, Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Three research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $1.00.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.